Table 2.

Progression events (ITT analysis)

	Arm 1 (N = 101)		Arm 2 (N = 72)		Arm 3 (N = 102)		Crude differences in cumulative incidence of PD9
	i.v. carboplatin + i.v. paclitaxel		i.p. cisplatin + i.v./i.p. paclitaxel		i.p. carboplatin + i.v./i.p. paclitaxel
	N	% (95% CI)	N	% (95% CI)	N	% (95% CI)	% (95% CI)
Progression or death at or before Month 9	39	38.6	25	34.7	25	24.5
		(29.1 to 48.1)		(23.7 to 45.7)		(16.2 to 32.9)
Arm 1 versus arm 3							14.1 (1.5 to 26.7)
Arm 2 versus arm 3							10.2 (−3.6 to 24.0)
Time of event
First relapse/progression on treatment	0		1		0
Objective progression only	0		0		0
CA125 progression only	0		0		0
Both objective and CA125 progressions	0		1		0
First relapse/Progression during follow-up	39		24		24
Objective progression only	17		5		7
CA125 progression only	0		0		0
Both objective and CA125 progressions	22		19		17
Death (without relapse/progression)	0		0		1

i.p., intraperitoneal; i.v., intravenous.